KalVista Stock Target Raised to $42 by Stifel Stifel raised KalVista’s price target to $42 on Mar 25, 2026 (Investing.com), citing stronger Ekterly demand—confirmatory quarterly sales and payer deals will determine if the valuation holds.

KalVista Stock Target Raised to $42 by Stifel: Stifel raised KalVista’s price target to $42 on Mar 25, 2026 (Investing.com), citing stronger Ekterly demand—confirmatory quarterly sales and payer deals will determine if the… 👈 Read full analysis #KalVista #StockMarket #Investing #Stifel #StockTarget

#HAE #HereditaryAngioedema #Ekterly #Sebetralstat #OralHAETreatment #OnDemandTherapy #ChronicIllness #RareDisease #Angioedema #PatientEmpowerment #SwellingRelief #SpoonieLife #HAECommunity #KalVista #BioNews #AngioedemaNews

If approved this October, patients may soon have a new needle‑free option to manage swelling
episodes quickly and confidently.

#HereditaryAngioedema #HAE #RareDisease #Sebetralstat #Ekterly #OrphanDrug #KalVista #OnDemandTherapy #BioNews #AngioedemaNews

Orsini Chosen as Specialty Pharmacy Partner for KalVista's EKTERLY® Treatment Orsini has been selected by KalVista Pharmaceuticals as a specialty pharmacy partner for EKTERLY®, a new oral therapy for hereditary angioedema.

Orsini Chosen as Specialty Pharmacy Partner for KalVista's EKTERLY® Treatment #United_States #Elk_Grove_Village #Orsini #KalVista #EKTERLY

💊 KalVista (KALV) is advancing its HAE treatment pipeline, securing key regulatory progress. 🚀 Could this biotech breakthrough drive long-term investor growth? Full analysis here: buff.ly/vsHQU9L #KalVista #KALV #BiotechStocks #HAETreatment #Investing